Trial · NCT00524225
IL-11 in Adults With Von Willebrand Disease Undergoing Surgery
NCT00524225, Phase 2, Terminated, Margaret Ragni; results first posted 2014-11-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IL-11 in Adults With Von Willebrand Disease Undergoing Surgery. Trials, record NCT00524225. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00524225
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IL-11 in Adults With Von Willebrand Disease Undergoing Surgery
- NCT number
- NCT00524225
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- Margaret Ragni
- Conditions
- Von Willebrand Disease
- Interventions
- Neumega (Oprelvekin, Interleukin 11, IL-11)
- First posted
- 2007-09-03
- Last updated
- 2019-06-11
- Results first posted
- 2014-11-07
- Limitations and caveats
- There were too few subjects for reporting in a manuscript.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Volume of Surgical Blood Loss | 4 weeks | Hemostatic efficacy was measured by estimated blood loss (cc) during the surgical procedure. |
| Primary | Volume of Blood Transfusion | 4 weeks | The volume of blood transfusion required (units of blood) after the surgical procedure. |
| Secondary | No. of Subjects With Detectable VWFmRNA (Von Willebrand Factor Messenger RNA). | 4 weeks per subject | The number of subjects with detectable VWFmRNA. |
| Secondary | Number of Subjects Who Experienced Adverse Events | The time frame is within 4 weeks of surgery. | mild headache, nausea |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Volume of Surgical Blood Loss | 4 weeks | cc | NUMBER | |
| PRIMARY | Volume of Blood Transfusion | 4 weeks | units of blood | NUMBER | |
| SECONDARY | No. of Subjects With Detectable VWFmRNA (Von Willebrand Factor Messenger RNA). | 4 weeks per subject | Even though three subjects were enrolled, none were assessed for VWFmRNA because the study stopped due to poor enrollment related to insurers requiring surgeries outside of UPMC. | ||
| SECONDARY | Number of Subjects Who Experienced Adverse Events | The time frame is within 4 weeks of surgery. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Volume of Surgical Blood Loss | Neumega (Interleukin 11, IL-11) | NA | cc | ||
| Volume of Blood Transfusion | Neumega (Interleukin 11, IL-11) | NA | units of blood | ||
| Number of Subjects Who Experienced Adverse Events | Neumega (Interleukin 11, IL-11) | Mild headache | 1 | participants | |
| Number of Subjects Who Experienced Adverse Events | Neumega (Interleukin 11, IL-11) | nausea | 1 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Neumega (Interleukin 11, IL-11) | 3 | |
| Overall Study | COMPLETED | Neumega (Interleukin 11, IL-11) | 3 | |
| Overall Study | NOT COMPLETED | Neumega (Interleukin 11, IL-11) | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | headache | Nervous system disorders | Neumega (Interleukin 11, IL-11) | 1 | 3 | 1 |
| other | nausea | Gastrointestinal disorders | Neumega (Interleukin 11, IL-11) | 1 | 3 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Neumega (Interleukin 11, IL-11) | ||
| Total, other adverse events | Neumega (Interleukin 11, IL-11) | 2 | 3 |
| Total, serious adverse events | Neumega (Interleukin 11, IL-11) | 0 | 3 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 18680527 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00524225
GET https://conductscience.org/api/trials/v1/NCT00524225/registered